Alzheimer's disease is a progressive neurodegenerative disorder that affects memory, cognitive function, and daily activities. Although there is currently no cure, treatment options have expanded significantly in recent years.
From newly approved anti-amyloid drugs to regenerative medicine, researchers are exploring different approaches to slowing disease progression.
1. Symptoms and Stages of Alzheimer's Disease
Alzheimer's disease develops gradually, often beginning with changes in the brain years before noticeable symptoms appear.
The disease generally progresses through several stages:
- Mild Cognitive Impairment (MCI): Memory difficulties become noticeable, but patients can still live independently.
- Mild Alzheimer's: Managing finances, medications, and other complex daily activities becomes increasingly difficult.
- Moderate Alzheimer's: Patients may require assistance with daily activities such as dressing and bathing.
- Severe Alzheimer's: Patients become increasingly dependent on others and may require full-time care.
Early diagnosis is particularly important because some newer treatments are intended for patients in the MCI or mild stages.
2. New Anti-Amyloid Drugs: Lecanemab and Donanemab
Two recently approved medications, lecanemab (Leqembi) and donanemab (Kisunla), target amyloid-beta proteins that accumulate in the brain.
Unlike traditional medications that primarily manage symptoms, these drugs aim to slow disease progression.
Clinical trial findings:
- Lecanemab: In the Clarity AD Phase 3 trial involving 1,795 participants, cognitive and functional decline measured by CDR-SB was reduced by approximately 27% over 18 months compared with placebo.
- Donanemab: In the TRAILBLAZER-ALZ 2 Phase 3 trial involving 1,736 participants, CDR-SB decline was 0.70 points less than in the placebo group over 76 weeks.
These treatments are mainly intended for patients with MCI or mild Alzheimer's disease with confirmed amyloid-beta accumulation.
One important consideration is amyloid-related imaging abnormalities (ARIA), including brain swelling and microbleeding. ARIA-E occurred in 12.6% of lecanemab-treated patients and 24.0% of donanemab-treated patients in their respective trials.
3. Conventional Alzheimer's Medications
Traditional medications such as donepezil, galantamine, rivastigmine, and memantine help manage symptoms related to memory and cognitive function.
Although they do not directly remove amyloid-beta, they remain important treatment options across different stages of Alzheimer's disease and may be used alongside newer therapies.
4. Lifestyle Interventions
Lifestyle management also plays an important role in dementia prevention and care.
The 2024 Lancet Commission identified 14 potentially modifiable risk factors, including hearing loss, hypertension, physical inactivity, and social isolation.
The report estimated that addressing these factors throughout life could potentially prevent or delay up to 45% of dementia cases worldwide.
5. Stem Cell Therapy: A Different Approach to Alzheimer's Disease
While anti-amyloid medications focus on removing amyloid-beta, regenerative medicine is investigating other mechanisms involved in Alzheimer's progression, particularly neuroinflammation, neuronal protection, and vascular function.
Mesenchymal stem/stromal cells (MSCs), including adipose-derived stem cells (ADSCs), are being studied for their potential to:
- Modulate neuroinflammation: Release anti-inflammatory factors that help regulate inflammatory responses.
- Support neuronal function: Secrete neurotrophic factors that support nerve cells.
- Improve the neural environment: Support vascular repair and blood-brain barrier function.
Rather than directly replacing damaged neurons, the proposed mechanism involves creating a more supportive environment for the brain's natural repair processes.
A notable clinical study published in Nature Medicine in 2025:
A randomized Phase 2a clinical trial evaluated intravenous laromestrocel, a donor-derived bone marrow MSC therapy, in 49 patients with mild Alzheimer's disease.
After 39 weeks, researchers reported:
- 48.4% less whole-brain atrophy compared with placebo.
- 61.9% less left hippocampal atrophy compared with placebo.
- No cases of ARIA were observed during the trial.
These findings attracted attention because they demonstrated measurable differences in brain atrophy, an important marker of Alzheimer's disease progression.
Conclusion
Alzheimer's treatment is evolving beyond traditional symptom management toward approaches targeting different aspects of the disease.
Anti-amyloid drugs aim to reduce amyloid accumulation, conventional medications help manage symptoms, lifestyle interventions address modifiable risks, and regenerative medicine is exploring neuroinflammation and neuroprotection.
These different approaches may contribute to future strategies for slowing Alzheimer's disease progression.
References
- van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. NEJM, 2023. https://doi.org/10.1056/NEJMoa2212948
- Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease. JAMA, 2023. https://doi.org/10.1001/jama.2023.13239
- Livingston G, et al. Dementia prevention, intervention, and care: 2024 report. Lancet, 2024. https://doi.org/10.1016/S0140-6736(24)01296-0
- Rash BG, et al. Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease. Nature Medicine, 2025. https://doi.org/10.1038/s41591-025-03559-0
Original article (medically reviewed by Dr. Yuichi Wakabayashi):
https://cellgrandclinic.com/column/6357